Published in J Biomed Biotechnol on June 07, 2010
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours. PLoS One (2016) 2.08
Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR. PLoS One (2011) 1.78
Capturing the metabolomic diversity of KRAS mutants in non-small-cell lung cancer cells. Oncotarget (2014) 1.04
A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas. J Exp Clin Cancer Res (2012) 1.04
Consumption of oxygen: a mitochondrial-generated progression signal of advanced cancer. Cell Death Dis (2012) 1.02
Morphological and molecular alterations in 1,2 dimethylhydrazine and azoxymethane induced colon carcinogenesis in rats. J Biomed Biotechnol (2010) 1.01
PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms. Theranostics (2014) 0.95
Mutant KRAS as a critical determinant of the therapeutic response of colorectal cancer. Genes Dis (2015) 0.94
Biology of colorectal cancer. Ecancermedicalscience (2015) 0.90
MicroRNA-5p and -3p co-expression and cross-targeting in colon cancer cells. J Biomed Sci (2014) 0.87
Circulating tumor cells: exploring intratumor heterogeneity of colorectal cancer. Cancer Biol Ther (2014) 0.86
KRAS p.G13D mutations are associated with sensitivity to anti-EGFR antibody treatment in colorectal cancer cell lines. J Cancer Res Clin Oncol (2012) 0.84
Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps. Discov Med (2014) 0.84
Ubiquitin-conjugating enzyme UBE2C is highly expressed in breast microcalcification lesions. PLoS One (2014) 0.84
Pancreatic cancer genomics: insights and opportunities for clinical translation. Genome Med (2013) 0.82
A functional proteomic method for biomarker discovery. PLoS One (2011) 0.81
KRAS Testing: A Tool for the Implementation of Personalized Medicine. Genes Cancer (2012) 0.81
A ceRNA analysis on LMNA gene focusing on the Hutchinson-Gilford progeria syndrome. J Clin Bioinforma (2013) 0.80
miR-1, regulated by LMP1, suppresses tumour growth and metastasis by targeting K-ras in nasopharyngeal carcinoma. Int J Exp Pathol (2016) 0.80
Identification of mutated core cancer modules by integrating somatic mutation, copy number variation, and gene expression data. BMC Syst Biol (2013) 0.79
Targeting KRas-dependent tumour growth, circulating tumour cells and metastasis in vivo by clinically significant miR-193a-3p. Oncogene (2016) 0.79
An NGS Workflow Blueprint for DNA Sequencing Data and Its Application in Individualized Molecular Oncology. Cancer Inform (2016) 0.78
Targeting the VEGF-C/VEGFR3 axis suppresses Slug-mediated cancer metastasis and stemness via inhibition of KRAS/YAP1 signaling. Oncotarget (2016) 0.77
Genomic alterations in pancreatic cancer and their relevance to therapy. World J Gastrointest Oncol (2015) 0.77
hERG1/Kv11.1 activation stimulates transcription of p21waf/cip in breast cancer cells via a calcineurin-dependent mechanism. Oncotarget (2016) 0.77
Mouse models for gastric cancer: Matching models to biological questions. J Gastroenterol Hepatol (2016) 0.77
MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. Sci Rep (2016) 0.76
Meganucleases Revolutionize the Production of Genetically Engineered Pigs for the Study of Human Diseases. Toxicol Pathol (2015) 0.76
Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas. Virchows Arch (2012) 0.76
Advances in gas chromatographic methods for the identification of biomarkers in cancer. J Cancer (2012) 0.76
Diagnosis of pancreatic lesions collected by endoscopic ultrasound-guided fine-needle aspiration using next-generation sequencing. Oncol Lett (2016) 0.75
Prognostic significance of KRAS gene mutations in colorectal cancer--preliminary study. J Med Life (2015) 0.75
Oncogene KRAS activates fatty acid synthase, resulting in specific ERK and lipid signatures associated with lung adenocarcinoma. Proc Natl Acad Sci U S A (2017) 0.75
Molecular Simulations of Solved Co-crystallized X-Ray Structures Identify Action Mechanisms of PDEδ Inhibitors. Biophys J (2015) 0.75
Oncogene Mutations in Colorectal Polyps Identified in the Norwegian Colorectal Cancer Prevention (NORCCAP) Screening Study. Clin Med Insights Pathol (2016) 0.75
Personalized medicine in sporadic pancreatic cancer without homologous recombination-deficiency: are we any closer? J Gastrointest Oncol (2016) 0.75
In Silico Screening of Mutated K-Ras Inhibitors from Malaysian Typhonium flagelliforme for Non-Small Cell Lung Cancer. Adv Bioinformatics (2014) 0.75
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell (1993) 64.62
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature (2005) 48.95
Identification of novel genes coding for small expressed RNAs. Science (2001) 44.44
The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature (2000) 39.31
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
Genetic alterations during colorectal-tumor development. N Engl J Med (1988) 26.82
ras genes. Annu Rev Biochem (1987) 22.59
bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell (2003) 22.14
Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol (2008) 20.89
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet (2002) 17.20
Reduced accumulation of specific microRNAs in colorectal neoplasia. Mol Cancer Res (2003) 17.13
Preinvasive and invasive ductal pancreatic cancer and its early detection in the mouse. Cancer Cell (2003) 15.43
Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acids Res (1989) 15.35
The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website. Br J Cancer (2004) 12.35
KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol (2008) 10.29
Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer (2007) 10.27
Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol (2005) 9.95
All ras proteins are polyisoprenylated but only some are palmitoylated. Cell (1989) 9.68
Prevalence of ras gene mutations in human colorectal cancers. Nature (1987) 9.23
The Ras-RasGAP complex: structural basis for GTPase activation and its loss in oncogenic Ras mutants. Science (1997) 9.21
Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. J Mol Diagn (2005) 6.00
Structure and organization of the human Ki-ras proto-oncogene and a related processed pseudogene. Nature (1983) 5.90
Detection of high incidence of K-ras oncogenes during human colon tumorigenesis. Nature (1987) 5.46
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
The Ras superfamily at a glance. J Cell Sci (2005) 4.83
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Association between coffee drinking and K-ras mutations in exocrine pancreatic cancer. PANKRAS II Study Group. J Epidemiol Community Health (1999) 4.43
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol (1993) 3.56
Human genome contains four genes homologous to transforming genes of Harvey and Kirsten murine sarcoma viruses. Proc Natl Acad Sci U S A (1982) 3.48
Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. Clin Cancer Res (2006) 3.40
Wildtype Kras2 can inhibit lung carcinogenesis in mice. Nat Genet (2001) 3.27
Characterization of a human colon/lung carcinoma oncogene. Nature (1983) 3.26
Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer (2001) 3.22
Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol Cancer Res (2007) 3.21
G-quadruplex formation within the promoter of the KRAS proto-oncogene and its effect on transcription. Nucleic Acids Res (2006) 3.09
Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev (2000) 3.05
The ras oncogenes in human lung cancer. Am Rev Respir Dis (1990) 2.31
Altered gene products are associated with activation of cellular rasK genes in human lung and colon carcinomas. Cell (1983) 2.27
Targeting c-kit mutations in solid tumors: scientific rationale and novel therapeutic options. Semin Oncol (2001) 2.20
Mode of action and application of Scorpion primers to mutation detection. Nucleic Acids Res (2000) 2.07
A genome-wide survey of RAS transformation targets. Nat Genet (2000) 2.06
The KRAS oncogene: past, present, and future. Biochim Biophys Acta (2005) 2.05
Ras oncogenes and their downstream targets. Biochim Biophys Acta (2007) 2.00
Mutational and kinetic analyses of the GTPase-activating protein (GAP)-p21 interaction: the C-terminal domain of GAP is not sufficient for full activity. Mol Cell Biol (1992) 1.93
Development of farnesyl transferase inhibitors: a review. Oncologist (2005) 1.90
Germline missense mutations affecting KRAS Isoform B are associated with a severe Noonan syndrome phenotype. Am J Hum Genet (2006) 1.78
ras oncogenes: their role in neoplasia. Eur J Clin Invest (1990) 1.68
Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol (2006) 1.68
K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. Carcinogenesis (1999) 1.67
High frequency of K-ras mutations in human colorectal hyperplastic polyps. Gut (1997) 1.61
The tumor suppressor protein p16INK4a. Exp Cell Res (1997) 1.57
The Ras/Raf/MEK/extracellular signal-regulated kinase pathway induces autocrine-paracrine growth inhibition via the leukemia inhibitory factor/JAK/STAT pathway. Mol Cell Biol (2003) 1.44
Heterogeneity of mutant versus wild-type Ki-ras in primary and metastatic colorectal carcinomas, and association of codon-12 valine with early mortality. J Pathol (1998) 1.41
Regional chromosomal localization of N-ras, K-ras-1, K-ras-2 and myb oncogenes in human cells. Nucleic Acids Res (1983) 1.41
K-ras point mutation detection in lung cancer: comparison of two approaches to somatic mutation detection using ARMS allele-specific amplification. Clin Chem (2000) 1.40
Effect of gefitinib ('Iressa', ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer (2004) 1.39
Mutation scanning using high-resolution melting. Biochem Soc Trans (2009) 1.38
Structure of small G proteins and their regulators. Acta Biochim Pol (2001) 1.36
Chromosomal localization of three human ras genes by in situ molecular hybridization. Somat Cell Mol Genet (1985) 1.35
Reversible intracellular translocation of KRas but not HRas in hippocampal neurons regulated by Ca2+/calmodulin. J Cell Biol (2005) 1.35
High detection rates of colorectal neoplasia by stool DNA testing with a novel digital melt curve assay. Gastroenterology (2008) 1.34
Electron microscopic imaging of Ras signaling domains. Methods (2005) 1.31
Mutations within the tyrosine kinase domain of EGFR gene specifically occur in lung adenocarcinoma patients with a low exposure of tobacco smoking. Br J Cancer (2006) 1.29
Farnesyltransferase inhibitors: a detailed chemical view on an elusive biological problem. Curr Med Chem (2008) 1.27
COLD-PCR: a new platform for highly improved mutation detection in cancer and genetic testing. Biochem Soc Trans (2009) 1.25
LOH of chromosome 12p correlates with Kras2 mutation in non-small cell lung cancer. Oncogene (2003) 1.23
Common occurrence of multiple K-RAS mutations in pancreatic cancers with associated precursor lesions and in biliary cancers. Oncogene (2002) 1.22
FLAG assay as a novel method for real-time signal generation during PCR: application to detection and genotyping of KRAS codon 12 mutations. Nucleic Acids Res (2007) 1.21
Presence of a Kirsten murine sarcoma virus ras oncogene in cells transformed by 3-methylcholanthrene. Mol Cell Biol (1983) 1.18
Approaching real-time molecular diagnostics: single-pair fluorescence resonance energy transfer (spFRET) detection for the analysis of low abundant point mutations in K-ras oncogenes. J Am Chem Soc (2003) 1.15
Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC). J Thorac Oncol (2009) 1.15
Prenylation-dependent association of Ki-Ras with microtubules. Evidence for a role in subcellular trafficking. J Biol Chem (1997) 1.14
Detection of K-Ras mutations in tumour samples of patients with non-small cell lung cancer using PNA-mediated PCR clamping. Br J Cancer (2009) 1.11
Chemosensitivity and radiosensitivity profiles of four new human epithelial ovarian cancer cell lines exhibiting genetic alterations in BRCA2, TGFbeta-RII, KRAS2, TP53 and/or CDNK2A. Cancer Chemother Pharmacol (2004) 1.07
Rapid identification of somatic mutations in colorectal and breast cancer tissues using mismatch repair detection (MRD). Hum Mutat (2008) 1.07
U.S. Food and Drug Administration approval: panitumumab for epidermal growth factor receptor-expressing metastatic colorectal carcinoma with progression following fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy regimens. Clin Cancer Res (2008) 1.06
The status and role of ErbB receptors in human cancer. Exp Mol Pathol (2008) 1.04
Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer. Pharmacotherapy (2008) 1.03
Allelotype analysis of mouse lung carcinomas reveals frequent allelic losses on chromosome 4 and an association between allelic imbalances on chromosome 6 and K-ras activation. Cancer Res (1994) 1.03
How does p21ras transform cells? Trends Genet (1991) 1.02
Ki-ras mutations in exocrine pancreatic cancer: association with clinico-pathological characteristics and with tobacco and alcohol consumption. PANK-ras I Project Investigators. Int J Cancer (1997) 1.02
DNA adducts, genetic polymorphisms, and K-ras mutation in human pancreatic cancer. Mutat Res (2002) 1.01
Role of proto-oncogene activation in carcinogenesis. Environ Health Perspect (1992) 0.99
Trimodality treatment in Stage III nonsmall cell lung carcinoma: prrognostic impact of K-ras mutations after neoadjuvant therapy. Cancer (2002) 0.97
Rapid screening assay for KRAS mutations by the modified smart amplification process. J Mol Diagn (2008) 0.95
The association of K-ras gene mutation and vascular endothelial growth factor gene expression in pancreatic carcinoma. Cancer (2001) 0.93
Acute lymphoblastic leukemia of childhood: identification of two distinct regions of deletion on the short arm of chromosome 12 in the region of TEL and KIP1. Blood (1996) 0.93
Activated kRas protects colon cancer cells from cucurbitacin-induced apoptosis: the role of p53 and p21. Biochem Pharmacol (2008) 0.93
Simplified Reverse Dot Blot Analyses for Detecting of ras Oncogene Mutations. Mol Diagn (1997) 0.92
An activating KRAS mutation in imatinib-resistant chronic myeloid leukemia. Leukemia (2008) 0.92
Structure determination of the Ras-binding domain of the Ral-specific guanine nucleotide exchange factor Rlf. Biochemistry (1998) 0.91
Detection of RAS mutations in archival testicular germ cell tumors by polymerase chain reaction and oligonucleotide hybridization. Genes Chromosomes Cancer (1992) 0.90
Chronic myeloid leukaemia: the evolution of gene-targeted therapy. Med J Aust (2008) 0.89
Mitogen-activated protein kinase-activated protein kinase 2 regulates tumor necrosis factor mRNA stability and translation mainly by altering tristetraprolin expression, stability, and binding to adenine/uridine-rich element. Mol Cell Biol (2006) 2.94
Cystic fibrosis mouse models. Am J Respir Cell Mol Biol (2006) 1.98
Preferential diaphragmatic weakness during sustained Pseudomonas aeruginosa lung infection. Am J Respir Crit Care Med (2003) 1.68
Biological importance of the two Toll-like receptors, TLR2 and TLR4, in macrophage response to infection with Candida albicans. FEMS Immunol Med Microbiol (2005) 1.50
NF-kappa B-mediated MyoD decay during muscle wasting requires nitric oxide synthase mRNA stabilization, HuR protein, and nitric oxide release. Mol Cell Biol (2005) 1.43
The expression of three genes in primary non-small cell lung cancer is associated with metastatic spread to the brain. Clin Cancer Res (2009) 1.39
Hemozoin increases IFN-gamma-inducible macrophage nitric oxide generation through extracellular signal-regulated kinase- and NF-kappa B-dependent pathways. J Immunol (2003) 1.29
Revisiting the role of cystic fibrosis transmembrane conductance regulator and counterion permeability in the pH regulation of endocytic organelles. Mol Biol Cell (2009) 1.29
Fragile X-related protein FXR1P regulates proinflammatory cytokine tumor necrosis factor expression at the post-transcriptional level. J Biol Chem (2004) 1.26
Lack of CFTR in skeletal muscle predisposes to muscle wasting and diaphragm muscle pump failure in cystic fibrosis mice. PLoS Genet (2009) 1.26
TLR2-dependent recognition of Streptococcus suis is modulated by the presence of capsular polysaccharide which modifies macrophage responsiveness. Int Immunol (2007) 1.25
Interleukin-1 gene cluster polymorphisms in sarcoidosis and idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2002) 1.22
Synthesis and cytotoxic activity of substituted 2-phenyl-3-hydroxy-4(1H)-quinolinones-7-carboxylic acids and their phenacyl esters. Eur J Med Chem (2006) 1.17
Fenretinide corrects newly found ceramide deficiency in cystic fibrosis. Am J Respir Cell Mol Biol (2007) 1.09
Chronic asthma-induced airway remodeling is prevented by toll-like receptor-7/8 ligand S28463. Am J Respir Crit Care Med (2007) 1.09
Comparison of the susceptibilities of C57BL/6 and A/J mouse strains to Streptococcus suis serotype 2 infection. Infect Immun (2008) 1.08
Distinct tryptophan catabolism and Th17/Treg balance in HIV progressors and elite controllers. PLoS One (2013) 1.08
Cutting edge: STAT1 and T-bet play distinct roles in determining outcome of visceral leishmaniasis caused by Leishmania donovani. J Immunol (2006) 1.06
N-glycoprotein SRMAtlas: a resource of mass spectrometric assays for N-glycosites enabling consistent and multiplexed protein quantification for clinical applications. Mol Cell Proteomics (2013) 1.05
A comparison of Direct sequencing, Pyrosequencing, High resolution melting analysis, TheraScreen DxS, and the K-ras StripAssay for detecting KRAS mutations in non small cell lung carcinomas. J Exp Clin Cancer Res (2012) 1.04
4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. J Med Chem (2006) 1.02
Nuclear translocation of beta-actin is involved in transcriptional regulation during macrophage differentiation of HL-60 cells. Mol Biol Cell (2010) 1.01
Critical role for phosphoinositide 3-kinase gamma in parasite invasion and disease progression of cutaneous leishmaniasis. Proc Natl Acad Sci U S A (2012) 1.00
The secretory leukocyte protease inhibitor is a type 1 insulin-like growth factor receptor-regulated protein that protects against liver metastasis by attenuating the host proinflammatory response. Cancer Res (2006) 0.99
A new era of targeting the ancient gatekeepers of the immune system: toll-like agonists in the treatment of allergic rhinitis and asthma. Int Arch Allergy Immunol (2014) 0.97
Cystic fibrosis fatty acid imbalance is linked to ceramide deficiency and corrected by fenretinide. Am J Respir Cell Mol Biol (2008) 0.97
Influence of gender and interleukin-10 deficiency on the inflammatory response during lung infection with Pseudomonas aeruginosa in mice. Immunology (2002) 0.96
Fenretinide promotes functional recovery and tissue protection after spinal cord contusion injury in mice. J Neurosci (2010) 0.96
New derivatives of silybin and 2,3-dehydrosilybin and their cytotoxic and P-glycoprotein modulatory activity. Bioorg Med Chem (2006) 0.96
RNA-binding protein HuR is required for stabilization of SLC11A1 mRNA and SLC11A1 protein expression. Mol Cell Biol (2005) 0.95
Identification of novel chromosomal regions associated with airway hyperresponsiveness in recombinant congenic strains of mice. Mamm Genome (2009) 0.94
Role of TLR2- and TLR4-mediated signaling in Mycobacterium tuberculosis-induced macrophage death. Cell Immunol (2010) 0.93
Secretory leukocyte protease inhibitor plays an important role in the regulation of allergic asthma in mice. J Immunol (2011) 0.92
Developmental validation of reduced-size STR Miniplex primer sets. J Forensic Sci (2007) 0.92
New lupane derived compounds with pro-apoptotic activity in cancer cells: synthesis and structure-activity relationships. J Med Chem (2003) 0.89
Fenretinide prevents the development of osteoporosis in Cftr-KO mice. J Cyst Fibros (2007) 0.89
Beneficial effects of secretory leukocyte protease inhibitor after spinal cord injury. Brain (2010) 0.88
Mitogen-activated protein kinase-activated protein kinase 2 (MK2) contributes to secondary damage after spinal cord injury. J Neurosci (2010) 0.88
Synthesis and cytotoxic activity of various 5-[alkoxy-(4-nitro-phenyl)-methyl]-uracils in their racemic form. Bioorg Med Chem Lett (2007) 0.87
Delayed cutaneous wound healing in mice lacking solute carrier 11a1 (formerly Nramp1): correlation with decreased expression of secretory leukocyte protease inhibitor. J Invest Dermatol (2006) 0.86
Androgenetic alopecia and current methods of treatment. Acta Dermatovenerol Alp Pannonica Adriat (2005) 0.86
Modulation of the allergic asthma transcriptome following resiquimod treatment. Physiol Genomics (2009) 0.86
Distinct role of MAPKAPK-2 in the regulation of TNF gene expression by Toll-like receptor 7 and 9 ligands. Mol Immunol (2007) 0.86
Distinct pattern of lung gene expression in the Cftr-KO mice developing spontaneous lung disease compared with their littermate controls. Physiol Genomics (2006) 0.86
MAPKAPK-2 signaling is critical for cutaneous wound healing. J Invest Dermatol (2010) 0.85
Sorafenib in combination with ionizing radiation has a greater anti-tumour activity in a breast cancer model. Anticancer Drugs (2012) 0.85
Recruitment of SWI/SNF complex is required for transcriptional activation of the SLC11A1 gene during macrophage differentiation of HL-60 cells. J Biol Chem (2011) 0.84
Merkel cell carcinoma of the gluteal region with ipsilateral metastasis into the pancreatic graft of a patient after combined kidney-pancreas transplantation. Onkologie (2010) 0.84
Fragile X related protein 1 clusters with ribosomes and messenger RNAs at a subset of dendritic spines in the mouse hippocampus. PLoS One (2011) 0.84
Synthesis and significant cytostatic activity of 7-hetaryl-7-deazaadenosines. J Med Chem (2011) 0.84
Protein tyrosine phosphatases regulate asthma development in a murine asthma model. J Immunol (2009) 0.84
Deregulated balance of omega-6 and omega-3 polyunsaturated fatty acids following infection by the zoonotic pathogen Streptococcus suis. Infect Immun (2014) 0.83
Ceramide in cystic fibrosis: a potential new target for therapeutic intervention. J Lipids (2010) 0.83
Fenretinide prevents inflammation and airway hyperresponsiveness in a mouse model of allergic asthma. Am J Respir Cell Mol Biol (2014) 0.82
6-(Het)aryl-7-deazapurine ribonucleosides as novel potent cytostatic agents. J Med Chem (2010) 0.81
Modulation of epithelial sodium channel (ENaC) expression in mouse lung infected with Pseudomonas aeruginosa. Respir Res (2005) 0.81
A study on the effects of degradation and template concentration on the amplification efficiency of the STR Miniplex primer sets. J Forensic Sci (2004) 0.81
Gene-metabolite expression in blood can discriminate allergen-induced isolated early from dual asthmatic responses. PLoS One (2013) 0.80
Importance of complement 3 and mannose receptors in phagocytosis of Paracoccidioides brasiliensis conidia by Nramp1 congenic macrophages lines. FEMS Immunol Med Microbiol (2006) 0.80
Role of SLC11A1 (formerly NRAMP1) in regulation of signal transduction induced by Toll-like receptor 7 ligands. FEMS Immunol Med Microbiol (2006) 0.80
Induction of nitric oxide synthase expression by lipopolysaccharide is mediated by calcium-dependent PKCα-β1 in alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol (2013) 0.80
Posttranscriptional gene expression regulation in CpG-activated macrophages depends on FXR1P RNA-binding protein. FEMS Immunol Med Microbiol (2007) 0.79
Polymorphisms in TOLL-like receptor genes and their roles in allergic asthma and atopy. Recent Pat Inflamm Allergy Drug Discov (2011) 0.79
The application of miniplex primer sets in the analysis of degraded DNA from human skeletal remains. J Forensic Sci (2006) 0.79
Frequency of 657del(5) mutation of the NBS1 gene in the Czech population by polymerase chain reaction with sequence specific primers. Cancer Genet Cytogenet (2002) 0.79
Synthesis, cytostatic, antimicrobial, and anti-HCV activity of 6-substituted 7-(het)aryl-7-deazapurine ribonucleosides. J Med Chem (2014) 0.79
Anticancer activity of natural cytokinins: a structure-activity relationship study. Phytochemistry (2010) 0.79
Batch immunoextraction method for efficient purification of aromatic cytokinins. J Chromatogr A (2005) 0.78
Preparation, preliminary screening of new types of steroid conjugates and their activities on steroid receptors. Steroids (2013) 0.78
Functional p53 in cells contributes to the anticancer effect of the cyclin-dependent kinase inhibitor roscovitine. J Cell Biochem (2009) 0.78
Fenretinide corrects the imbalance between omega-6 to omega-3 polyunsaturated fatty acids and inhibits macrophage inflammatory mediators via the ERK pathway. PLoS One (2013) 0.78
[KRAS mutation testing in therapeutic algorithm for treatment of metastatic colorectal carcinoma]. Cas Lek Cesk (2011) 0.78
Synthesis and cytotoxicity of some D-mannose click conjugates with aminobenzoic acid derivatives. Carbohydr Res (2012) 0.77
Structural basis for inhibition of mycobacterial and human adenosine kinase by 7-substituted 7-(Het)aryl-7-deazaadenine ribonucleosides. J Med Chem (2014) 0.77
Synthesis of 5-[alkoxy-(4-nitro-phenyl)-methyl]-uridines and study of their cytotoxic activity. Eur J Med Chem (2010) 0.77
Bioequivalence of two brands of citalopram 40 mg tablets after single oral administration to healthy volunteers. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2005) 0.76
Brg-1 mediates the constitutive and fenretinide-induced expression of SPARC in mammary carcinoma cells via its interaction with transcription factor Sp1. Mol Cancer (2010) 0.76
Pharmacological modulation of Th17. Recent Pat Inflamm Allergy Drug Discov (2009) 0.76
Immunohistochemical study of the apoptotic mechanisms in the intestinal mucosa during children's coeliac disease. Virchows Arch (2003) 0.76
Lycopene improves the distorted ratio between AA/DHA in the seminal plasma of infertile males and increases the likelihood of successful pregnancy. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2013) 0.76
New frontiers in the therapeutic management of transplant rejection. Curr Pharm Des (2006) 0.75
Abrupt expression of TLR4 in TLR4-deficient macrophages imposes a selective disadvantage: genetic evidence for TLR4-dependent responses to endogenous, nonmicrobial stimuli. J Immunol (2006) 0.75
[Possibility of using the determination of minimal residual disease in pancreatic adenocarcinoma using real-time RT-PCR--a pilot study]. Cas Lek Cesk (2010) 0.75
Fetal colon cell line FHC exhibits tumorigenic phenotype, complex karyotype, and TP53 gene mutation. Cancer Genet Cytogenet (2010) 0.75
Metallacarborane sulfamides: unconventional, specific, and highly selective inhibitors of carbonic anhydrase IX. J Med Chem (2019) 0.75
Recombinant congenic strains of mice: a new tool for the genetic dissection of efficacy and toxicity of adjuvants. Vaccine (2003) 0.75
p53--prognostic factor of malignant transformation of Barrett's esophagus. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub (2005) 0.75
Synthesis of various 5-alkoxymethyluracil analogues and structure-cytotoxic activity relationship study. Carbohydr Res (2011) 0.75
Cyclocondensation reaction of heterocyclic carbonyl compounds. Part XIII: synthesis and cytotoxic activity of some 3,7-diaryl-5-(3,4,5-trimethoxyphenyl)pyrazolo[4,3-e][1,2,4]triazines. Eur J Med Chem (2008) 0.75
[A retrospective analysis of trastuzumab-based therapy in metastatic breast cancer patients at Masaryk Memorial Cancer Institute. Identification of predictive factors]. Klin Onkol (2008) 0.75
Synthesis of 2-aryl-4-(benzimidazol-2-yl)-1,2-dihydro[1,2,4]triazino-[4,5-a]benzimidazol-1-one derivatives with preferential cytotoxicity against carcinoma cell lines. Eur J Med Chem (2007) 0.75
2-phenylsubstituted-3-hydroxyquinolin-4(1H)-one-carboxamides: Structure-cytotoxic activity relationship study. ACS Comb Sci (2010) 0.75
Interaction of ionizing radiation and ZRBA1, a mixed EGFR/DNA-targeting molecule. Anticancer Drugs (2009) 0.75
Promoter deletion analysis using a dual-luciferase reporter system. Methods Mol Biol (2013) 0.75